CAB Tri-Axis Dominant-Primary Series V-PR

Mentha × piperita

Peppermint

Tier VCAB Tri-Axis Dominant-Primary Series

Target Trait

2.8×

fold-change

Cooling-dominant tri-axis A+B modulated fold-change

Technical Specifications

SKU

SS-F-M3-02098

Genomic Edits

GC Content

44.9%

Construct Length

6,887 bp

Promoter System

Ubiquitin / T7

Expression System

Protoplast PEG-fusion

Host Strain

PEG-mediated

Receptor Target

TRPM8 + Polyphenol-astringency axis + TAS2R38 (suppression)

IFI Score

280

Pathway Edits

TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
Tri-axis metabolic flux partitioning hub for concurrent CAB pathway operation
Cross-pathway regulatory circuit for cooling-dominant CAB triple-axis expression
Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, Polyphenol-astringency axis, and TAS2R38 (suppression) pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CAB) with cross-pathway flux managementPEG-mediated co-transfection of axis constructs for rapid phenotypic screening of multi-axis combinations

IFI Subscale Profile

IFI Profile

IFI-S

—

IFI-U

—

IFI-B

—

IFI-K

—

IFI-C

—

IFI-P

—

IFI-A

—

IFI-F

—

Use Case

Tier V CAB triple-axis construct for advanced multi-modal sensory architecture combining cooling, astringency, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$9999 · Tier V License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-M All Modalities